4-Sep-2026
NovaBridge Biosciences to Participate in September Investor Conferences
Globe Newswire (Thu, 27-Aug 7:00 AM ET)
Globe Newswire (Thu, 20-Aug 7:00 AM ET)
Globe Newswire (Thu, 13-Aug 5:00 PM ET)
NovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026
Globe Newswire (Fri, 24-Jul 5:00 PM ET)
Market Chameleon (Mon, 29-Jun 7:43 AM ET)
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
Globe Newswire (Mon, 29-Jun 7:00 AM ET)
Globe Newswire (Tue, 16-Jun 7:00 AM ET)
Market Chameleon (Tue, 6-Jan 4:55 AM ET)
Market Chameleon (Tue, 6-Jan 4:21 AM ET)
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
Novabridge Biosciences - American Depositary Shares trades on the NASDAQ stock market under the symbol NBP.
As of September 4, 2026, NBP stock price was flat at $1.80 with 70,267 million shares trading.
NBP has a beta of 1.10, meaning it tends to be more sensitive to market movements. NBP has a correlation of 0.04 to the broad based SPY ETF.
NBP has a market cap of $207.48 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that NBP belongs to (by Net Assets): SPEM, SBIO, QQQS, EWX, GXC.
NBP support price is $1.74 and resistance is $1.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NBP shares will trade within this expected range on the day.